Chemours Co: Form 10-K for the period ended Dec 31, 2023
Filed with the SEC on Mar 27, 2024 and accepted by EDGAR at Mar 27, 2024, 20:08 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-10-01 to 2023-12-31 | $1.36bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 12 months2023-01-01 to 2023-12-31 | $6.03bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2023-10-01 to 2023-12-31 | $1.11bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 12 months2023-01-01 to 2023-12-31 | $4.72bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 12 months2023-01-01 to 2023-12-31 | $1.31bn | us-gaap:GrossProfit |
| Research and development | 12 months2023-01-01 to 2023-12-31 | $108.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2023-01-01 to 2023-12-31 | $1.29bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 12 months2023-01-01 to 2023-12-31 | $208.0m | us-gaap:InterestExpense |
| Income tax | 12 months2023-01-01 to 2023-12-31 | −$81.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-10-01 to 2023-12-31 | −$18.0m | us-gaap:NetIncomeLoss |
| Net income | 12 months2023-01-01 to 2023-12-31 | −$238.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-10-01 to 2023-12-31 | −$0.12 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2023-01-01 to 2023-12-31 | −$1.60 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-10-01 to 2023-12-31 | −$0.12 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months2023-01-01 to 2023-12-31 | −$1.60 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2023-01-01 to 2023-12-31 | 148,912,397 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2023-01-01 to 2023-12-31 | $556.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2023-01-01 to 2023-12-31 | $370.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 12 months2023-01-01 to 2023-12-31 | $149.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 12 months2023-01-01 to 2023-12-31 | $69.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2023-12-31 | $1.20bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-12-31 | $3.83bn | us-gaap:AssetsCurrent |
| Total assets | At period end2023-12-31 | $8.25bn | us-gaap:Assets |
| Current liabilities | At period end2023-12-31 | $2.49bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-12-31 | $7.51bn | us-gaap:Liabilities |
| Long-term debt | At period end2023-12-31 | $3.99bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2023-12-31 | $51.0m | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2023-12-31 | $737.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-24-037171. Last ingested by Listed: Oct 24, 2026, 15:14 ET. Listed shows no prices and gives no investment advice.